Liraglutide lowered body mass, slowed weight gain and improved health markers in kids ages 6 through 11, according to ...
The study concentrates on the FDA-approved injectable medications semaglutide and liraglutide. A study conducted by the ...
Liraglutide treatment significantly lowers BMI in obese children aged 6 to <12, but gastrointestinal side effects prompt the ...
Currently, there are no approved medications for treating nonmonogenic, nonsyndromic obesity in children under 12. While ...
Evidence shows that blockbuster weight-loss medications can reduce obesity even in children aged 6–11, but their long-term ...
Liraglutide is the first GLP-1 agonist to show benefit in this age group and could provide young patients a much-needed ...
For patients with obesity receiving semaglutide or liraglutide, weight reduction at one year is associated with medication active agent.
The Clinical Trials Arena team investigates assets in infectious diseases, metabolic disorders, oncology and ophthalmology.